These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 30537506)
1. The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. Van den Eynde M; Mlecnik B; Bindea G; Fredriksen T; Church SE; Lafontaine L; Haicheur N; Marliot F; Angelova M; Vasaturo A; Bruni D; Jouret-Mourin A; Baldin P; Huyghe N; Haustermans K; Debucquoy A; Van Cutsem E; Gigot JF; Hubert C; Kartheuser A; Remue C; Léonard D; Valge-Archer V; Pagès F; Machiels JP; Galon J Cancer Cell; 2018 Dec; 34(6):1012-1026.e3. PubMed ID: 30537506 [TBL] [Abstract][Full Text] [Related]
2. Multiverse of immune microenvironment in metastatic colorectal cancer. Van den Eynde M; Mlecnik B; Bindea G; Galon J Oncoimmunology; 2020 Sep; 9(1):1824316. PubMed ID: 33457100 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. Mlecnik B; Van den Eynde M; Bindea G; Church SE; Vasaturo A; Fredriksen T; Lafontaine L; Haicheur N; Marliot F; Debetancourt D; Pairet G; Jouret-Mourin A; Gigot JF; Hubert C; Danse E; Dragean C; Carrasco J; Humblet Y; Valge-Archer V; Berger A; Pagès F; Machiels JP; Galon J J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922789 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968 [TBL] [Abstract][Full Text] [Related]
5. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells? Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
8. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases. Maker AV; Ito H; Mo Q; Weisenberg E; Qin LX; Turcotte S; Maithel S; Shia J; Blumgart L; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI Cancer Immunol Res; 2015 Apr; 3(4):380-8. PubMed ID: 25600439 [TBL] [Abstract][Full Text] [Related]
9. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752 [TBL] [Abstract][Full Text] [Related]
12. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Silva-Figueroa A; Villalobos P; Williams MD; Bassett RL; Clarke CN; Lee JE; Busaidy NL; Perrier ND Surgery; 2018 Nov; 164(5):960-964. PubMed ID: 30033186 [TBL] [Abstract][Full Text] [Related]
13. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506 [TBL] [Abstract][Full Text] [Related]
14. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565 [TBL] [Abstract][Full Text] [Related]
15. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Mlecnik B; Bindea G; Kirilovsky A; Angell HK; Obenauf AC; Tosolini M; Church SE; Maby P; Vasaturo A; Angelova M; Fredriksen T; Mauger S; Waldner M; Berger A; Speicher MR; Pagès F; Valge-Archer V; Galon J Sci Transl Med; 2016 Feb; 8(327):327ra26. PubMed ID: 26912905 [TBL] [Abstract][Full Text] [Related]
16. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. Herfs M; Roncarati P; Koopmansch B; Peulen O; Bruyere D; Lebeau A; Hendrick E; Hubert P; Poncin A; Penny W; Piazzon N; Monnien F; Guenat D; Mougin C; Prétet JL; Vuitton L; Segers K; Lambert F; Bours V; de Leval L; Valmary-Degano S; Quick CM; Crum CP; Delvenne P Br J Cancer; 2018 May; 118(10):1302-1312. PubMed ID: 29700411 [TBL] [Abstract][Full Text] [Related]
17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
18. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer. Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]